8.5Summary

A variety of surgical methods are applied to the treatment of PVR. In the more severe cases, it is useful to prepare the patient for the likelihood of three operations, one to flatten most of the retina, a second to flatten the remaining retina and a final procedure to remove silicone oil.

References

(1992) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110(6):780–792

Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, doubleblind, controlled clinical trial. Ophthalmology 108(7):1179–1183

Barr CC, Lai MY, Lean JS, Linton KL, Trese M, Abrams G, Ryan SJ, Azen SP (1993) Postoperative intraocular pressure abnormalities in the Silicone Study. Silicone Study Report 4. Ophthalmology 100(11):1629–1635

Benson SE, Schlottmann PG, Bunce C, Xing W, Charteris DG (2006) Optical coherence tomography analysis of the macula after vitrectomy surgery for retinal detachment. Ophthalmology 113(7):1179–1183. doi:S0161-6420(06)00118-7[pii],10.1016/j.ophtha.2006.01.039

Blumenkranz M, Hernandez E, Ophir A, Norton EW (1984) 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91(2):122–130

Bonnet M, Fleury J, Guenoun S, Yaniali A, Dumas C, Hajjar C (1996) Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234(12):739–743

Bourke RD, Cooling RJ (1996) Vascular consequences of retinectomy. Arch Ophthalmol 114(2):155–160

Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C (2004) A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111(12):2240–2245 Coll GE, Chang S, Sun J, Wieland MR, Berrocal MH (1995) Perfluorocarbon liquid in the management of retinal detachment with

proliferative vitreoretinopathy. Ophthalmology 102(4):630–638 Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H (1989)

Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 107(8):1147–1151

Cox MS, Trese MT, Murphy PL (1986) Silicone oil for advanced proliferative vitreoretinopathy. Ophthalmology 93(5):646–650

Cox MS, Azen SP, Barr CC, Linton KL, Diddie KR, Lai MY, Freeman HM, Irvine A (1995) Macular pucker after successful surgery for proliferative vitreoretinopathy. Silicone Study Report 8. Ophthalmology 102(12):1884–1891

Diddie KR, Azen SP, Freeman HM, Boone DC, Aaberg TM, Lewis H, Radtke ND, Ryan SJ (1996) Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Ophthalmology 103(7):1092–1099

Duquesne N, Bonnet M, Adeleine P (1996) Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234(11):677–682

Fisher YL, Shakin JL, Slakter JS, Sorenson JA, Shafer DM (1988) Perfluoropropane gas, modified panretinal photocoagulation, and vitrectomy in the management of severe proliferative vitreoretinopathy. Arch Ophthalmol 106(9):1255–1260

Glaser BM, Cardin A, Biscoe B (1987) Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 94(4):327–332

Glaser BM, Vidaurri-Leal J, Michels RG, Campochiaro PA (1993) Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 100(4):466–470

Han DP, Rychwalski PJ, Mieler WF, Abrams GW (1994) Management of complex retinal detachment with combined relaxing retinotomy and intravitreal perfluoro-n-octane injection. Am J Ophthalmol 118(1):24–32

Iverson DA, Ward TG, Blumenkranz MS (1990) Indications and results of relaxing retinotomy. Ophthalmology 97(10):1298–1304

Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW (2000) Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol 84(5):506–511

Lam RF, Cheung BT, Yuen CY, Wong D, Lam DS, Lai WW (2008) Retinal redetachment after silicone oil removal in proliferative vitreoretinopathy: a prognostic factor analysis. Am J Ophthalmol 145(3):527–533. doi:S0002-9394(07)00922-1[pii],10.1016/j.ajo. 2007.10.015

Lewis H, Aaberg TM (1991) Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 111(1):15–19

Lewis H, Verdaguer JI (1996) Surgical treatment for chronic hypotony and anterior proliferative vitreoretinopathy. Am J Ophthalmol 122(2): 228–235

Lewis H, Aaberg TM, Abrams GW, McDonald HR, Williams GA, Mieler WF (1989) Subretinal membranes in proliferative vitreoretinopathy. Ophthalmology 96(9):1403–1414

Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112(2):159–165 Moisseiev J, Glaser BM (1989) New and previously unidentified retinal breaks in eyes with recurrent retinal detachment with proliferative

vitreoretinopathy. Arch Ophthalmol 107(8):1152–1154

O’Connell SR, Majji AB, Humayun MS, De Juan E Jr (2000) The surgical management of hypotony. Ophthalmology 107(2):318–323 Quiram PA, Gonzales CR, Hu W, Gupta A, Yoshizumi MO, Kreiger

AE, Schwartz SD (2006) Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology 113(11):2041-2047. doi:S0161-6420(06)00725-1[pii]10.1016/j. ophtha.2006.05.039

Schwartz SD, Kreiger AE (1998) Proliferative vitreoretinopathy: a natural history of the fellow eye. Ophthalmology 105(5):785–788 Scott IU, Flynn HW, Lai M, Chang S, Azen SP (2000) First operation

anatomic success and other predictors of postoperative vision after complex retinal detachment repair with vitrectomy and silicone oil tamponade. Am J Ophthalmol 130(6):745–750

Scott IU, Flynn HW Jr, Murray TG, Feuer WJ (2003) Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 136(3):454–463

Stappler T, Williams R, Wong D (2010) F4H5: a novel substance for the removal of silicone oil from intraocular lenses. Br J Ophthalmol 94(3):364–367. doi:bjo.2009.161489[pii],10.1136/bjo.2009.161489

Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, O’Donnell JJ (1983) Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 96(1):33–42

Stolba U, Binder S, Velikay M, Datlinger P, Wedrich A (1995) Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications. Br J Ophthalmol 79(12):1106–1110

Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ (2004) Prevalence and risk factors for proliferative vitreoretinopathy in eyes with

rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 137(6):1105–1115

Vidaurri-Leal J, de Bustros S, Michels RG (1984) Surgical treatment of giant retinal tears with inverted posterior retinal flaps. Am J Ophthalmol 98(4):463–466

Wiedemann P, Hilgers RD, Bauer P, Heimann K (1998) Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy:

results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126(4):550–559

Yorston DB, Wood ML, Gilbert C (2002) Retinal detachment in East Africa. Ophthalmology 109(12):2279–2283